- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06742190
En studie for å vurdere effektiviteten og sikkerheten til Empasiprubart versus IVIg hos voksne med multifokal motorisk nevropati (Empassion)
En fase 3, randomisert, dobbeltblindet, dobbeltdummy studie som evaluerer effektiviteten og sikkerheten til Empasiprubart versus intravenøst immunglobulin hos voksne med multifokal motorisk nevropati
The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.
More information can be found here: https://clinicaltrials.argenx.com/empassion
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Parkville, Australia, 3050
- Royal Melbourne Hospital
-
Southport, Australia, 4215
- Gold Coast University Hospital
-
Sydney, Australia, 2609
- Brain and Mind Center
-
Woolloongabba, Australia, 4102
- Princess Alexandra Hospital
-
-
-
-
-
Edegem, Belgia, 2650
- UZ Antwerpen
-
Leuven, Belgia, 3000
- UZ Leuven
-
Liège, Belgia, 4000
- Hôpital de la Citadelle
-
-
-
-
-
Ribeirão Preto, Brasil, 14051
- Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto
-
Rio de Janeiro, Brasil, 22620-172
- Sociedade de Ensino Superior Estacio de Sa Ltda
-
Salvador, Brasil, 40290-000
- Escola Bahiana de Medicina e Saude Publica
-
São Paulo, Brasil, 04038-002
- PSEG Centro de Pesquisa Clínica
-
-
-
-
-
Gatineau, Canada, J8Y 1W2
- Neuro-Outaouais Clinic
-
London, Canada, N6A 5A5
- London Health Sciences Centre
-
Vancouver, Canada, V6Z 2H2
- St. Paul's Neurology Associates
-
-
-
-
-
Aarhus, Danmark, 8200
- Aarhus Universitetshospital
-
Copenhagen, Danmark, 2100
- Rigshospitalet-Inge Lehmanns Vej 8
-
-
-
-
Arizona
-
Scottsdale, Arizona, Forente stater, 85251
- HonorHealth Neurology - Bob Bove Neuroscience Institute - Neurology
-
-
California
-
Pomona, California, Forente stater, 91767
- The Neurology Group
-
Rancho Mirage, California, Forente stater, 92270
- Samir Macwan, M.D., Inc.
-
San Francisco, California, Forente stater, 94143
- University of California San Francisco
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado - Anschutz Cancer Pavilion (Neuro Onc Clinic)
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06511
- Yale University School of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Medstar Health Research Institute
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33486
- EZR Research LLC
-
Coral Springs, Florida, Forente stater, 33067
- Healthcare Innovations Institute, LLC
-
Miami, Florida, Forente stater, 33136
- University of Miami Miller School of Medicine
-
Tampa, Florida, Forente stater, 33612
- University of South Florida
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Indiana University Health Neuroscience Center
-
-
Kansas
-
Fairway, Kansas, Forente stater, 66205
- University of Kansas Medical Center
-
-
Maryland
-
Columbia, Maryland, Forente stater, 21044
- Perelman Center for Advanced Medicine
-
Columbia, Maryland, Forente stater, 21044
- UC Irvine - MDA ALS and Neuromuscular Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55414
- University of Minnesota
-
-
New York
-
Amherst, New York, Forente stater, 14226
- Dent Neurologic Institute Amherst
-
New York, New York, Forente stater, 10032
- Columbia University Medical Center
-
-
North Carolina
-
Morrisville, North Carolina, Forente stater, 27560
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- The Cleveland Clinic Foundation
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Oregon Health and Science University
-
-
Texas
-
Austin, Texas, Forente stater, 78759-8402
- National Neuromuscular Research Institute
-
Houston, Texas, Forente stater, 77094
- NeuroCarePlus
-
-
-
-
-
Bordeaux, Frankrike, 33000
- CHU de Bordeaux - Hôpital Pellegrin
-
Brest, Frankrike, 29609
- CHU de Brest - Hôpital La Cavale Blanche
-
Bron, Frankrike, 69500
- Hospices Civils de Lyon - Hôpital Pierre Wertheimer
-
Le Kremlin-Bicêtre, Frankrike, 94270
- AP-HP - Hôpital Bicêtre
-
Lille, Frankrike, 59000
- Hôpital Roger Salengro
-
Limoges, Frankrike, 87042
- CHU Limoges - Dupuytren 1
-
Marseille, Frankrike, 13385
- AP-HM- Hôpital de La Timone
-
Marseille, Frankrike, 13005
- AP-HM- Hôpital de La Timone
-
Nice, Frankrike, 6001
- CHU de Nice-Hôpital Pasteur
-
Paris, Frankrike, 75013
- AP-HP - Hôpital de la Pitié Salpétrière
-
Strasbourg, Frankrike, 67200
- CHU de Strasbourg - Hôpital de Hautepierre
-
-
-
-
-
Chaïdári, Hellas, 124 62
- University General Hospital ''ATTIKON'' - General Hospital of West Attica H AGIA VARVARA
-
Thessaloniki, Hellas, 546 36
- AHEPA University General Hospital of Thessaloniki
-
-
-
-
-
Florence, Italia, 50134
- Azienda Ospedaliera Universitaria Careggi
-
Genova, Italia, 16132
- Ospedale Policlinico San Martino IRCCS
-
Gussago, Italia, 25064
- Fondazione Serena Onlus - Centro Clinico NeMO Brescia
-
Messina, Italia, 98124
- Az. Ospedaliera Universitaria Policlinico G. Martino
-
Milan, Italia, 20132
- Ospedale San Raffaele S.r.l.
-
Milan, Italia, 20133
- Azienda Ospedaliero-Universitaria San Luigi Gonzaga
-
Roma, Italia, 00189
- Azienda Ospedaliero-Universitaria Sant'Andrea
-
Roma, Italia, 133
- Fondazione PTV Policlinico Tor Vergata
-
Rozzano, Italia, 20089
- IRCCS Istituto Clinico Humanitas
-
-
-
-
-
Bunkyō City, Japan, 113-8431
- Juntendo University Hospital
-
Bunkyō City, Japan, 113-8519
- Institute of Science Tokyo Hospital
-
Chūōku, Japan, 260-8677
- Chiba University Hospital
-
Kodaira, Japan, 187-8502
- National Center of Neurology and Psychiatry
-
Nagoya, Japan, 4668560
- Nagoya University Hospital
-
Ube, Japan, 755-0067
- Yamaguchi University Hospital
-
tabashi City, Japan, 173-8606
- Teikyo University Hospital
-
-
-
-
-
Shanghai, Kina, 200040
- Huashan Hospital Fudan University
-
-
-
-
-
Riga, Latvia, LV-1002
- Pauls Stradins Clinical University Hospital
-
-
-
-
-
Kaunas, Litauen, 50161
- Hospital of Lithuanian University of Health Sciences Kauno klinikos
-
-
-
-
-
Amsterdam, Nederland, 1105 AZ
- Amsterdam UMC
-
-
-
-
-
Oslo, Norge, 0450
- Oslo Universitetssykehus HF, Ullevål
-
-
-
-
-
Bydgoszcz, Polen, 85-065
- MICS Centrum Medyczne Bydgoszcz
-
Katowice, Polen, 40-689
- Centrum Medyczne Neurologia Slaska
-
Krakow, Polen, 30-688
- SP ZOZ Szpital Uniwersytecki w Krakowie
-
Lublin, Polen, 20--64
- Galen Clinic -- Lublin
-
Warsaw, Polen, 02-097
- UCK WUM, Centralny Szpital Kliniczny
-
-
-
-
-
Porto, Portugal, 4099-001
- ULS de Santo António, EPE - Hospital de Santo António
-
-
-
-
-
Belgrade, Serbia, 11000
- University Clinical Center of Serbia
-
-
-
-
-
Bratislava, Slovakia, 821 01
- Univerzitna nemocnica Bratislava
-
Martin, Slovakia, 036 59
- Univerzitna nemocnica MARTIN
-
-
-
-
-
Ljubljana, Slovenia, 1000
- University Medical Centre Ljubljana
-
-
-
-
-
Alicante, Spania, 03010
- Hospital General Universitario Dr. Balmis
-
Badalona, Spania, 08916
- Hospital Universitario Germans Trias i Pujol
-
Barcelona, Spania, 08035
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spania, 08041
- Hospital de La Santa Creu i Sant Pau
-
Barcelona, Spania, 08907
- Hospital Universitario de Bellvitge
-
Madrid, Spania, 28039
- Hospital Clinico San Carlos
-
Madrid, Spania, 48013
- Hospital Universitario de Basurto
-
Málaga, Spania, 29004
- Hospital Quironsalud Malaga
-
San Sebastián, Spania, 8035
- Hospital Universitario de Donostia
-
-
-
-
-
Glasgow, Storbritannia, G51 4TF
- Queen Elizabeth University Hospital
-
Oxford, Storbritannia, OX3 7LE
- John Radcliffe Hospital
-
Salford, Storbritannia, M6 8HD
- Salford Royal Hospital
-
Sheffield, Storbritannia, S10 2JF
- Royal Hallamshire Hospital
-
Taunton, Storbritannia, TA1 5DA
- Musgrove Park Hospital
-
-
-
-
-
Bern, Sveits, 3010
- Inselspital - Universitätsspital Bern
-
-
-
-
-
Brno, Tsjekkia, 625 00
- Fakultni nemocnice Brno
-
Hradec Králové, Tsjekkia, 500 05
- Fakultni nemocnice Hradec Kralove
-
Prague, Tsjekkia, 128 08
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
-
Essen, Tyskland, 45147
- Universitätsklinikum Essen
-
Göttingen, Tyskland, 37075
- Universität Georg August
-
Lübeck, Tyskland, 23538
- Universitätsklinikum Schleswig-Holstein - Campus Lübeck
-
Münster, Tyskland, 48149
- Universitätsklinikum Münster
-
Potsdam, Tyskland, 14471
- Alexianer - MVZ St. Josefs-Krankenhaus Potsdam GmbH
-
Würzburg, Tyskland, 97080
- Universitätsklinikum Würzburg
-
-
-
-
-
Vienna, Østerrike, 1090
- Universitätsklinikum AKH Wien
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Is at least 18 years of age and the local legal age of consent for clinical studies
- Has a confirmed diagnosis of definite or probable MMN at screening according to the EFNS/PNS 2010 guidelines
- Has responded to IVIg in the past 5 years.
- Is receiving IVIg at a treatment interval of once every 2, 3, 4, or 5 weeks, and a dose of 0.4 to 2.0 g/kg body weight per cycle
- Is receiving a maintenance regimen (no change in frequency, and no change in dose >10%) of IVIg for at least 8 weeks before screening (or at least 10 weeks for participants receiving IVIg once every 5 weeks)
- Minimum converted weekly IVIg dose of ≥0.125 g/kg
- Has documented immunization against encapsulated bacterial pathogens (N meningitidis and S pneumoniae) within 5 years of screening or is willing to receive immunization at least 14 days before first study drug administration
Exclusion Criteria:
- Besides the indication under study, known autoimmune disease (eg, SLE) or any other medical condition that would confound the study results or put the participant at undue risk
- Clinical signs or symptoms suggestive of neuropathies other than MMN, such as motor neuron disease (eg, bulbar signs, brisk reflexes) or other inflammatory neuropathies (eg, sensory neuropathy)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Part A - empasiprubart + IVIg-placebo
During the double blinded - double dummy part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm |
Intravenous infusion of empasiprubart A placebo resembling the IVIg treatment |
|
Aktiv komparator: Part A - IVIg + empasiprubart-placebo
During the double blinded - double dummy part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm |
Intravenous infusion of IVIg A placebo resembling the empasiprubart treatment |
|
Eksperimentell: Part B - empasiprubart
After completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg) |
Intravenous infusion of empasiprubart |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from baseline in grip strength (4-week average) in the most affected hand at week 24
Tidsramme: Up to 24 weeks
|
Up to 24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Endring fra baseline i grepsstyrke (3-dagers glidende gjennomsnitt) i den mest berørte hånden ved uke 24
Tidsramme: Opptil 24 uker
|
Opptil 24 uker
|
|
|
Forekomst av AE, AESI og SAE
Tidsramme: Opptil 24 uker (del A), opptil 120 uker (del B)
|
Opptil 24 uker (del A), opptil 120 uker (del B)
|
|
|
Serumkonsentrasjoner over tid av empasiprubart
Tidsramme: Opptil 24 uker (del A), opptil 120 uker (del B)
|
Opptil 24 uker (del A), opptil 120 uker (del B)
|
|
|
Prosentvise endringer fra baseline i fri C2 og total C2 over tid
Tidsramme: Opptil 24 uker (del A), opptil 120 uker (del B)
|
Opptil 24 uker (del A), opptil 120 uker (del B)
|
|
|
Forekomst av anti-medikamentantistoffer (ADA) mot empasiprubart i serum
Tidsramme: Opptil 24 uker (del A), opptil 120 uker (del B)
|
Opptil 24 uker (del A), opptil 120 uker (del B)
|
|
|
Forekomst av NAb mot empasiprubart i serum
Tidsramme: Opptil 24 uker (del A), opptil 120 uker (del B)
|
Opptil 24 uker (del A), opptil 120 uker (del B)
|
|
|
Endring fra baseline i grepstyrke (3-dagers glidende gjennomsnitt) for den minst berørte hånden over tid
Tidsramme: Opptil 24 uker
|
Opptil 24 uker
|
|
|
AUC for endring fra baseline i grepsstyrke (3-dagers glidende gjennomsnitt) for de mest og minst berørte hendene
Tidsramme: Opptil 24 uker
|
Opptil 24 uker
|
|
|
Endring fra baseline i Rasch-Transformed Fatigue Severity Scale (RT-FSS) poengsum over tid
Tidsramme: Opptil 24 uker (del A), opptil 120 uker (del B)
|
Opptil 24 uker (del A), opptil 120 uker (del B)
|
|
|
Endring fra baseline i score for fysiske komponenter og mentale komponenter for 12-elements kortskjemaundersøkelse (SF-12) over tid
Tidsramme: Opptil 24 uker (del A), opptil 120 uker (del B)
|
Opptil 24 uker (del A), opptil 120 uker (del B)
|
|
|
Andel deltakere og skift fra baseline etter hver dimensjon på EQ-5D-5L skalaen
Tidsramme: Opptil 24 uker (del A), opptil 120 uker (del B)
|
Opptil 24 uker (del A), opptil 120 uker (del B)
|
|
|
Endringer fra baseline i grepsstyrke (3-dagers glidende gjennomsnitt; begge hender)
Tidsramme: Opptil 120 uker (del B)
|
Opptil 120 uker (del B)
|
|
|
Change from baseline in MMN-RODS centile score at week 24
Tidsramme: Up to 24 weeks
|
The 25-Item Rasch-Built Overall Disability Scale for MMN (MMN-RODS) is a questionnaire about the relationship between daily activities and the participants' health |
Up to 24 weeks
|
|
Change from baseline in mMRC-14 sum score
Tidsramme: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
The modified Medical Research Council (mMRC)-14 is a questionnaire where each muscle group is scored from 0 (paralysis) to 5 (normal strength). A higher value indicates better muscle strength. The total score is based on the sum of both the left and right side of the body. |
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
|
PGI-C actual value
Tidsramme: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
The Patient Global Impression of Change (PGI-C) is a 7-point scale depicting a participant's rating of overall improvement. The lower the score, the better the improvement. |
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
|
Change from baseline in CAP-PRI total score
Tidsramme: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
The Chronic Acquired Polyneuropathy Patient-Reported Index (CAP-PRI) includes the assessment of 15 items. Items will be scored 0 (not at all), 1 (a little bit), or 2 (a lot), yielding a total score that ranges from 0 to 30. |
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
|
Percentage change from baseline in time to complete the 9-HPT with the dominant hand
Tidsramme: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
The 9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function. Both the dominant and nondominant hands will be tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand). |
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
|
Percentage change from baseline in time to complete the 9-HPT with the nondominant hand over time
Tidsramme: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
The 9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function. Both the dominant and nondominant hands will be tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand). |
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
|
Change from baseline in sum scores for mMRC-10 and mMRC-14 restricted to the 2 most affected muscle groups over time
Tidsramme: Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
The modified Medical Research Council (mMRC) is a questionnaire where each muscle group is scored from 0 (paralysis) to 5 (normal strength). A higher value indicates better muscle strength. The total score is based on the sum of both the left and right side of the body. |
Up to 24 weeks (Part A), Up to 120 weeks (Part B)
|
|
Proportion of participants and shift from baseline over time by level of severity on PGI-S
Tidsramme: Up to 24 weeks
|
Patient Global Impression of Severity (PGIS) is a 7-point scale depicting a participant's rating of overall illness severity. Higher scores mean a higher severity. |
Up to 24 weeks
|
|
Changes from baseline in MMN-RODS centile score
Tidsramme: Up to 120 weeks (part B)
|
The 25-Item Rasch-Built Overall Disability Scale for MMN (MMN-RODS) is a questionnaire about the relationship between daily activities and the participants' health |
Up to 120 weeks (part B)
|
|
Actual values of PGI-S over time
Tidsramme: Up to 120 weeks (part B)
|
Patient Global Impression of Severity (PGIS) is a 7-point scale depicting a participant's rating of overall illness severity. Higher scores mean a higher severity. |
Up to 120 weeks (part B)
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ARGX-117-2302
- 2024-516473-72-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .